Study Summary
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Fludarabine + Cyclophosphamide + CAR-NK-CD19 CellsDRUG
fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Union Hospital, Huazhong University of Science and Technology | Wuhan | Hubei | China |
| Union Hospital, Huazhong University of Science and Technology | Wuhan | Hubei | China |